TL;DR CNBC

Obesity drug industry could be worth $200 billion within the decade, says Barclays, as market valuations grow

Publishing timestamp: 2023-04-28 01:08:04

Summary

The weight-loss drug industry could be worth up to $200 billion within the next decade, according to Barclays bank. The industry is attracting attention from investors and public health authorities as global obesity rates continue to rise. Pharmaceutical companies such as Novo Nordisk and Eli Lily are developing weight-loss drugs that rely on an active ingredient called semaglutide, which imitates a naturally occurring gut hormone to regulate appetite and lead to weight loss. However, controversy and questions remain about the effectiveness and long-term health benefits of these drugs. A forthcoming study could provide further insight into the cardiovascular benefits of weight-loss drugs and their wider-reaching applications. Investors are advised to take a long-term view when considering stocks in the weight-loss drug industry.

Sentiment: MIXED

Tickers: NOVO.B-DK,  NVO,  LLY, 

Keywords: pharmaceuticals,  biotech and pharmaceuticals,  business news,  biotechnology,  novo nordisk a/s,  eli lilly and co, 

Source: https://www.cnbc.com/2023/04/28/obesity-drugs-to-be-worth-200-billion-in-next-10-years-barclays-says.html